These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 2231576)

  • 21. Adrenoceptors on blood cells from patients with primary Raynaud's phenomenon.
    Jeremy JY; Gill J; Barradas MA; Mikhailidis DP
    Clin Sci (Lond); 1991 Sep; 81(3):447. PubMed ID: 1655348
    [No Abstract]   [Full Text] [Related]  

  • 22. Primary Raynaud's phenomenon. Age of onset and pathogenesis in a prospective study of 424 patients.
    Planchon B; Pistorius MA; Beurrier P; De Faucal P
    Angiology; 1994 Aug; 45(8):677-86. PubMed ID: 8048777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Diagnosis of vascular acrosyndromes].
    Senet P
    Ann Dermatol Venereol; 2015; 142(8-9):513-8. PubMed ID: 26169898
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Raynaud's phenomenon-an update on diagnosis, classification and management.
    Pauling JD; Hughes M; Pope JE
    Clin Rheumatol; 2019 Dec; 38(12):3317-3330. PubMed ID: 31420815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Raynaud's phenomenon in Northern Sweden: a population-based nested case-control study.
    Stjernbrandt A; Pettersson H; Liljelind I; Nilsson T; Wahlström J
    Rheumatol Int; 2019 Feb; 39(2):265-275. PubMed ID: 30128730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Thermographic assessment of Raynaud's phenomenon in childhood mixed connective tissue disease].
    Yokota S; Kuriyama T; Takahashi Y; Mori M; Shike H; Ibe M; Mitsuda T; Aihara Y
    Ryumachi; 1994 Dec; 34(6):955-60. PubMed ID: 7863385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-traumatic Raynaud's phenomenon following volar plate injury.
    Chodakiewitz YG; Daniels AH; Kamal RN; Weiss AP
    R I Med J (2013); 2014 Apr; 97(4):24-6. PubMed ID: 24660212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Raynaud's phenomenon.
    Lally EV
    Curr Opin Rheumatol; 1992 Dec; 4(6):825-36. PubMed ID: 1457277
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of Raynaud's phenomenon in a healthy Spanish population.
    Riera G; Vilardell M; Vaqué J; Fonollosa V; Bermejo B
    J Rheumatol; 1993 Jan; 20(1):66-9. PubMed ID: 8441168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis of Raynaud's phenomenon.
    Herrick AL
    Rheumatology (Oxford); 2005 May; 44(5):587-96. PubMed ID: 15741200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-Traumatic Raynaud's Phenomenon: A Case Report.
    Cheok LJ; Ooi CK
    J Emerg Med; 2017 Jun; 52(6):e237-e238. PubMed ID: 28256352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Raynaud's phenomenon.
    Wigley FM
    Curr Opin Rheumatol; 1993 Nov; 5(6):773-84. PubMed ID: 8117541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Raynaud's phenomenon.
    Devgire V; Hughes M
    Br J Hosp Med (Lond); 2019 Nov; 80(11):658-664. PubMed ID: 31707892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study.
    DiGiacomo RA; Kremer JM; Shah DM
    Am J Med; 1989 Feb; 86(2):158-64. PubMed ID: 2536517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Acrocyanosis, Raynaud's phenomenon and digital gangrene in a case of systemic lupus erythematosus].
    Montuori R; Riccardi C
    Minerva Med; 1968 Feb; 59(10):515-21. PubMed ID: 5642234
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacotherapy of Raynaud's phenomenon.
    Belch JJ; Ho M
    Drugs; 1996 Nov; 52(5):682-95. PubMed ID: 9118818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Raynaud's phenomena of occupational origin].
    Hatron PY; Frimat P; Hachulla E
    Rev Prat; 1998 Oct; 48(15):1653-8. PubMed ID: 9814066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Raynaud's phenomena: diagnostic and treatment study].
    Priollet P
    Rev Prat; 1998 Oct; 48(15):1659-64. PubMed ID: 9814067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of Botulinum Toxin Type A and its Potential Effect on Exacerbated Raynaud's Phenomenon in Hospitalized Scleroderma Patients.
    Seyedmardani SM; Aghdashi MA; Soltani S; Zonouz GK
    Curr Rheumatol Rev; 2022; 18(1):48-57. PubMed ID: 34636314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.